var data={"title":"Idursulfase: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Idursulfase: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/231534?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=idursulfase-drug-information\" class=\"drug drug_general\">see &quot;Idursulfase: Drug information&quot;</a> and <a href=\"topic.htm?path=idursulfase-patient-drug-information\" class=\"drug drug_patient\">see &quot;Idursulfase: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708563\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hypersensitivity reactions:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Life-threatening anaphylactic reactions have occurred in some patients during and up to 24 hours after idursulfase infusions. Anaphylaxis, presenting as respiratory distress, hypoxia, hypotension, urticaria, and/or angioedema of throat or tongue, has been reported to occur during and after idursulfase infusions, regardless of duration of the course of treatment. Closely observe patients during and after administration and be prepared to manage anaphylaxis. Inform patients of the signs and symptoms of anaphylaxis and have them seek immediate medical care should symptoms occur. Patients with compromised respiratory function or acute respiratory disease may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions, and require additional monitoring.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3151893\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Elaprase</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5376743\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Elaprase</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6915106\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Enzyme</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6915116\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=idursulfase-drug-information\" class=\"drug drug_general\">see &quot;Idursulfase: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pediatric: <b>Mucopolysaccharidosis type II (MPS II, Hunter syndrome): Note:</b> Current consensus opinion recommends initiation of therapy as early as possible following diagnosis (Scarpa 2011):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 16 months to &lt;5 years: Limited data available: IV: 0.5 mg/kg once weekly (Muenzer 2011; Scarpa 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &ge;5 years and Adolescents: IV: 0.5 mg/kg once weekly </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adult: <b>Mucopolysaccharidosis type II (MPS II, Hunter syndrome):</b> IV: 0.5 mg/kg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3151950\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Elaprase: 6 mg/3 mL (3 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3151894\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6915117\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">IV: Administer using an infusion set containing a 0.2 micron low protein-binding inline filter. Infuse at an initial rate of 8 mL/hour for the first 15 minutes. If tolerated, may increase rate by 8 mL/hour increments every 15 minutes up to maximum infusion rate of 100 mL/hour. Rate may be decreased, temporarily stopped, or discontinued based on tolerance. Initial infusion should be over 3 hours; if tolerated, subsequent infusions may be gradually reduced to a 1-hour infusion. Total infusion time should not exceed 8 hours. <b>Note:</b> For subsequent doses, current guidelines suggest that shortened infusion time of 1 hour is not desirable and increased the risk of infusion-related reaction; extra precautions should be used (Scarpa 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3151933\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Store vials under refrigeration at 2&#730;C to 8&#730;C (36&#730;F to 46&#730;F). Protect from light, do not freeze or shake. Should be used immediately after dilution in NS. However, solution for infusion may be stored under refrigeration for up to 24 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6915107\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Replacement therapy in mucopolysaccharidosis II (MPS II, Hunter syndrome) (FDA approved in ages &ge;5 years and adults) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3151890\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Elaprase may be confused with Elspar</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3151929\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac arrhythmia, flushing, hypotension, pulmonary embolism, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, dizziness, fatigue, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Erythema, pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Angioedema, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Antibody development (neutralizing), development of IgG antibodies</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Musculoskeletal pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Otitis (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough, pneumonia (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylaxis, cyanosis, loss of consciousness, respiratory distress, respiratory failure, seizure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3151923\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Canadian labeling:</i> Hypersensitivity to idursulfase or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3151924\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity/anaphylactoid reactions: <b>[US Boxed Warning]: Serious hypersensitivity reactions, including fatal life-threatening anaphylactic reactions, have been reported during and within 24 hours after infusion. Anaphylaxis may present as respiratory distress, hypoxia, hypotension, urticaria, and/or tongue/throat angioedema. Monitor closely during and after infusion. Appropriate medical support should be readily available. Patients with compromised respiratory function or acute respiratory disease are at risk of respiratory disease exacerbation due to hypersensitivity; additional monitoring may be required.</b> Discontinue immediately if anaphylactic or acute reaction occurs. Patients experiencing initial severe or refractory reactions may need prolonged monitoring. Antihistamines, corticosteroids and/or decreased infusion rates may be used to manage subsequent infusions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antibody formation: Development of anti-idursulfase IgG antibodies has been reported in 51% of patients; may increase incidence of hypersensitivity reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute febrile/respiratory illness: Hypersensitivity reactions may occur. Use caution and consider delaying treatment in patients with compromised respiratory function or acute febrile or respiratory illness; may be at increased risk for life-threatening complications from hypersensitivity reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid overload: Use with caution in patients at risk for fluid overload or in conditions where fluid restriction is indicated (eg, acute underlying respiratory illness, compromised cardiac and/or respiratory function); conditions may be exacerbated during infusion. Extended observation may be necessary for some patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Genetic mutations: Use with caution in patients with severe genetic mutations (eg, complete gene deletion, large gene rearrangement, nonsense, frameshift or splice site mutations); may increase risk of hypersensitivity reactions, serious adverse reactions, and antibody development.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Registry: Patients and healthcare providers are encouraged to participate in the Hunter Outcome Survey, intended to monitor disease progression, patient outcomes, and long-term effects of therapy. For more information, refer to www.elaprase.com or call OnePathsm at 1-866-888-0660.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27233034\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Per the manufacturer, a small, open-labeled evaluation of the safety and efficacy of 53 weeks of therapy in 28 pediatric patients &le;5 years of age showed enzyme replacement with idursulfase reduced splenic volume similar to older pediatric patients but data did not support improvement in other disease-related symptoms (which were undefined) or long-term clinical outcomes (which were undefined). <b>Note:</b> Proving clinical benefit of therapy for disease-related symptoms in this population is challenging due to age-related compliance with evaluation techniques (eg, walking capacity evaluations, FEV) (Muenzer 2011).  A larger observation trial (n=124) of patients &lt;6 years (including infants) showed weekly administration of idursulfase produced a significant decrease in hepatic volume and a reduction in urine GAG levels similar to that in older pediatric patients (Muenzer 2011). Guidelines suggest the initiation of idursulfase therapy at the time of diagnosis to delay the development of permanent life-threatening disease manifestations (Scarpa 2011)   </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When compared to pediatric patients &gt;7 years, the patients &le;7 years of age were shown to have more frequent development of anti-idursulfase IgG antibodies (68% vs 51%) and neutralizing antibodies (79% vs 41%).  In patients &lt;5 years of age, an association between the presence of antibodies and reduced systemic idursulfase exposure has been observed; this has not been reported in older pediatric patients (&ge;5 years of age). Younger pediatric patients have also been shown to develop neutralizing antibodies earlier in therapy (at week 9 vs 27) and at higher titers.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299508\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6220952\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=100321&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3151900\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3151921\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Animal reproduction studies have not been conducted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6915118\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Monitor for infusion-related and hypersensitivity reactions; pulmonary function, oxygen saturation; blood pressure </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3151937\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Idursulfase is a recombinant form of iduronate-2-sulfatase, an enzyme needed to hydrolyze the mucopolysaccharides dermatan sulfate and heparan sulfate in various cells. Accumulation of these polysaccharides can lead to various manifestations of disease, including physical changes, CNS involvement, cardiac, respiratory, and mobility dysfunction. Replacement of this enzyme has been shown to improve walking capacity in patients with a deficiency. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3151939\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Varies dependent upon age and presence of antibodies (particularly patients &lt;7.5 years): V<sub>ss</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 16 months to &lt;7.5 years: Week 1: 394 &plusmn; 423 mL/kg; Week 27: Antibody negative: 272 &plusmn; 112 mL/kg; antibody positive: 829 &plusmn; 636 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;7.5 years, Adolescents, and Adults &lt;27 years: Mean range: 213 to 254 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Varies dependent upon age and presence of antibodies (particularly patients &lt;7.5 years)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 16 months to &lt;7.5 years: Week 1: 160 &plusmn; 69 minutes; Week 27: Antibody negative: 134 &plusmn; 19 minutes; antibody positive: 84 &plusmn; 46 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;7.5 years, Adolescents, and Adults &lt;27 years: Mean range: 44 to 48 minutes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322949\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Elaprase Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg/3 mL (3 mL): $3,763.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5378699\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Elaprase (AT, AU, BB, BE, BG, BR, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, HR, HU, IE, IL, IT, JP, KR, LT, LU, LV, MT, MY, NL, NO, NZ, PL, PT, RU, SE, SG, SI, SK, TH, TR, TW);</li>\n      <li>elaprase (RO);</li>\n      <li>Elapraza (UA);</li>\n      <li>Elapraze (QA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Elaprase (idursulfase) [prescribing information]. Cambridge, MA: Shire Human Genetic Therapies Inc: June 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Muenzer J, Beck M, Eng CM, et al, &ldquo;Long-Term, Open-Labeled Extension Study of Idursulfase in the Treatment of Hunter Syndrome,&rdquo; <i>Genet Med</i>, 2011; 13(2):95-101.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/idursulfase-pediatric-drug-information/abstract-text/21150784/pubmed\" target=\"_blank\" id=\"21150784\">21150784</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Muenzer J, Beck M, Giugliani R, et al. Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey. <i>Genet Med</i>. 2011;13(2):102-109.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/idursulfase-pediatric-drug-information/abstract-text/21233716 /pubmed\" target=\"_blank\" id=\"21233716 \">21233716 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Muenzer J, Wraith JE, Beck M, wet al, &ldquo;A Phase II/III Clinical Study of Enzyme Replacement Therapy With Idursulfase in Mucopolysaccharidosis II (Hunter Syndrome),&rdquo; <i>Genet Med</i>, 2006, 8(8):465-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/idursulfase-pediatric-drug-information/abstract-text/16912578/pubmed\" target=\"_blank\" id=\"16912578\">16912578</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scarpa M, Alm&aacute;ssy Z, Beck M, et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. <i>Orphanet J Rare Dis</i>. 2011;6:72 <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/idursulfase-pediatric-drug-information/abstract-text/22059643 /pubmed\" target=\"_blank\" id=\"22059643 \">22059643 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 100321 Version 29.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708563\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F3151893\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F5376743\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F6915106\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F6915116\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F3151950\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F3151894\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F6915117\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F3151933\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F6915107\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3151890\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F3151929\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F3151923\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F3151924\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F27233034\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299508\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6220952\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F3151900\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3151921\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F6915118\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F3151937\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F3151939\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322949\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5378699\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/100321|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=idursulfase-drug-information\" class=\"drug drug_general\">Idursulfase: Drug information</a></li><li><a href=\"topic.htm?path=idursulfase-patient-drug-information\" class=\"drug drug_patient\">Idursulfase: Patient drug information</a></li></ul></div></div>","javascript":null}